论文部分内容阅读
目的：观察CD_3AK抗CD3单克隆抗体）的活化及对肿瘤细胞的杀伤活性。方法：以不同的肿瘤细胞为靶细胞，以人外周血淋巴细胞为效应细胞，在体外用不同浓度的抗CD3单克隆抗体和／或IL-2进行激活，用MTT法观察细胞毒杀伤作用。结果：CD3AK的扩增率较LAK高一个数量级，且对不同的肿瘤细胞均有杀伤作用。其18h杀伤均大于4h。结论：由于CD3AK较LAK对IL-2的需要量少，扩增率高，而比LAK更有临床应用发展前景。
Objective: To observe the activation of CD_3AK anti-CD3 monoclonal antibody and its killing activity against tumor cells. Methods: Different tumor cells as target cells and human peripheral blood lymphocytes as effector cells were activated in vitro with different concentrations of anti-CD3 monoclonal antibody and/or IL-2. MTT assay was used to observe cytotoxicity. RESULTS: The amplification rate of CD3AK was an order of magnitude higher than that of LAK, and it had a killing effect on different tumor cells. Its 18h killing is greater than 4h. Conclusions: Because CD3AK requires less IL-2 than LAK, the amplification rate is high, and it is more clinically applicable than LAK.